Helen V Danesh-Meyer1, Leonard A Levin. 1. Department of Ophthalmology, University of Auckland Medical School, Auckland, New Zealand. helendm@gmail.com
Abstract
PURPOSE: To review the current status of neuroprotection in ophthalmic disease. DESIGN: Perspective. METHODS: Published and unpublished data on neuroprotection in neurologic and ophthalmologic diseases were reviewed and interpreted. RESULTS: Almost all clinical studies of neuroprotection in neurologic and ophthalmologic disease so far have failed to show efficacy, despite encouraging preclinical studies. CONCLUSIONS: Achievement of consensus on how to design and execute translational research in neuroprotection in ophthalmic disease would optimize the use of resources and would hasten the development and approval of effective neuroprotective agents.
PURPOSE: To review the current status of neuroprotection in ophthalmic disease. DESIGN: Perspective. METHODS: Published and unpublished data on neuroprotection in neurologic and ophthalmologic diseases were reviewed and interpreted. RESULTS: Almost all clinical studies of neuroprotection in neurologic and ophthalmologic disease so far have failed to show efficacy, despite encouraging preclinical studies. CONCLUSIONS: Achievement of consensus on how to design and execute translational research in neuroprotection in ophthalmic disease would optimize the use of resources and would hasten the development and approval of effective neuroprotective agents.
Authors: Felix Ulbrich; Ulrich Goebel; Daniel Böhringer; Petar Charalambous; Wolf Alexander Lagrèze; Julia Biermann Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-07-21 Impact factor: 3.117